Company news
-
The patent of CD47xPD-L1 bispecific antibody was authorized by US patent officeImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the self-developed bispecific antibody drug (Project No.: IMM2505) targeting both CD47 and PD-L1 was recently authorized by the U.S. Patent Office (application No.: 16/170024). The invention ......2020-12-15 -
The IMM0306 project of ImmuneOnco was accepted by FDA for clinical trialOn December 10, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (Project No.: IMM0306) independently developed by the company and targeting CD47 and CD20 simultaneously has obtained the application(Applic......2020-12-10 -
Clinical trial study on expanding new indications of IMM01 projectImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (project number: IMM01) in China was accepted by NMPA for clinical trial application (IND) for new indications (MM, AML and MDS). This is......2020-11-21 -
The bispecific antibody drugs targeting PD-L1 and VEGF simultaneously were accepted by NMPA clinical trialOn October 21, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (Project No.: IMM2510) independently developed by the company and simultaneously targeting PD-L1 and VEGF was accepted for NMPA clinical tria......2020-10-21 -
ImmuneOnco announced the completion of Round B financing of $25 millionOn October 10, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the completion of round B financing of $25 million. This financing is led by Lilly Asia Fund (LAV) and followed by LYFE capital; the Round A investor, Li Cheng assets, continu......2020-10-10